Hong Xinjie, Wei Zhentao, Zuo Tian, Xu Liyu, Zhang Haohang, Xu Tao, Wang Dongmei, Lu Chengyin, Hou Lijun
Department of Neurosurgery, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
School of Basic Medical Sciences, Navy Medical University, Shanghai, China.
Front Neurol. 2025 Jun 13;16:1595194. doi: 10.3389/fneur.2025.1595194. eCollection 2025.
Gliomas are the most common and aggressive malignant tumors of the central nervous system. Their complex biology and adaptive resistance mechanisms pose major obstacles to existing treatment strategies. This study aims to analyze research published over the past 5 years to identify emerging trends, effective therapeutic agents, and novel treatment strategies.
Relevant articles on glioma drug therapy were retrieved from the Web of Science Core Collection for the period 2020-2024. Bibliometric analyses were performed using CiteSpace and VOSviewer to examine authorship, institutional and national contributions, journal impact, and keyword distributions. A total of 9,701 articles were included in the analysis.
China leads in publication volume on glioma research, followed by the United States. Liu Yang from China is the most prolific author in this field over the past 5 years. Institutions from China and the United States are the primary contributors to this area of research. Bibliometric analysis identified four major thematic clusters: glioma treatment, drug delivery, immunotherapy and the tumor microenvironment, and the molecular mechanisms underlying glioma cell behavior.
This systematic analysis of glioma treatment research over the past 5 years highlights key global research hotspots and emerging trends. Drug delivery and immunotherapy have gained increasing attention as promising therapeutic approaches. Advances in glioma treatment are expected to improve patient outcomes.
胶质瘤是中枢神经系统最常见且侵袭性最强的恶性肿瘤。其复杂的生物学特性和适应性耐药机制对现有治疗策略构成了重大障碍。本研究旨在分析过去5年发表的研究，以确定新出现的趋势、有效的治疗药物和新的治疗策略。
从科学网核心合集检索2020年至2024年期间关于胶质瘤药物治疗的相关文章。使用CiteSpace和VOSviewer进行文献计量分析，以考察作者身份、机构和国家贡献、期刊影响力以及关键词分布。总共9701篇文章纳入分析。
中国在胶质瘤研究的发表量方面领先，其次是美国。中国的刘洋是过去5年该领域发表文章最多的作者。中国和美国的机构是该研究领域的主要贡献者。文献计量分析确定了四个主要主题集群：胶质瘤治疗、药物递送、免疫治疗与肿瘤微环境以及胶质瘤细胞行为的分子机制。
对过去5年胶质瘤治疗研究的这一系统分析突出了全球关键研究热点和新出现的趋势。药物递送和免疫治疗作为有前景的治疗方法受到越来越多的关注。胶质瘤治疗的进展有望改善患者预后。
